Abstract
To evaluate the effect of oat bran supplementation on cardiovascular risk components of patients with mental disorders. A before-and-after study, no control group. Cardiovascular risk indicators were assessed at baseline (M0), 90 (M1), 180 days (M2) and 180 days after supplementation (M3). Of the 45 patients admitted to a psychiatric institution using antipsychotics, more than two thirds had high cardiovascular risk assessed by abdominal obesity. Forty-six point seven percent were overweight and 31.1% metabolic syndrome. Oat bran was effective in reducing serum cholesterol (M0-M1), HDL-cholesterol (M1-M2), triglycerides (M1-M2), (M2-M3) and (M1-M3). In M3, there was a statistical difference for all indicators evaluated. Oat bran supplementation was effective in improving triglyceride, total cholesterol and HDL-cholesterol levels, suggesting that it is a therapeutic option for cardiovascular risk control in patients with psychiatric disorders.
Highlights
Schizophrenia is a neuropsychiatric disorder that causes work disability, and most patients are unable to achieve full functional recovery, causing burden to the caregiver [1]
With the advancement of research and development of new drugs for the treatment of mental disorders, second generation antipsychotics (SGA) have emerged, with numerous advantages over previous ones, and less extrapyramidal side effects[1,2,3]. Chronic use of this therapy is associated with the onset of metabolic changes that significantly increase the risk of death from cardiovascular disease (CVD), today the leading cause of death in individuals with schizophrenia[4]
The results showed that, unlike the body mass index (BMI) and Waist circumference (WC) values, which did not show statistical difference, the waist/height ratio (WHtR) in the first 180 days responded significantly (p
Summary
Schizophrenia is a neuropsychiatric disorder that causes work disability, and most patients are unable to achieve full functional recovery, causing burden to the caregiver [1]. Chronic use of this therapy is associated with the onset of metabolic changes that significantly increase the risk of death from cardiovascular disease (CVD), today the leading cause of death in individuals with schizophrenia[4] These individuals have a higher risk of metabolic disorders when compared to the general population, mainly due to risk factors for CVD, such as abdominal obesity, assessed by waist circumference by height ratio[5], dyslipidemia, hypertension and type 2 diabetes mellitus[4,6,7,8]. The explanations for these changes are diverse, arising from the disease itself - increased stress[9], inflammatory response[9], drug side effect[4] and factors linked to genetic components[9] and lifestyle, as a sedentary lifestyle and inadequate food consumption[8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
